Lineage Cell Therapeutics Stock Today
| LCTX Stock | USD 0.57 0.04 6.56% |
Performance0 of 100
| Odds Of DistressLess than 10
|
Lineage Cell is trading at 0.57 as of the 1st of December 2024; that is 6.56 percent decrease since the beginning of the trading day. The stock's open price was 0.61. Lineage Cell has less than a 10 % chance of experiencing some financial distress in the next two years of operation, but has generated negative returns over the last 90 days. Equity ratings for Lineage Cell Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 7th of December 2023 and ending today, the 1st of December 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 6th of March 1992 | Category Healthcare | Classification Health Care |
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California. The company has 220.42 M outstanding shares of which 15.94 M shares are now shorted by private and institutional investors with about 35.21 trading days to cover. More on Lineage Cell Therapeutics
Moving against Lineage Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Lineage Stock Highlights
| President CEO | MBA MA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Tel Aviv 60, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsLineage Cell can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Lineage Cell's financial leverage. It provides some insight into what part of Lineage Cell's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Lineage Cell Therapeutics (LCTX) is traded on NYSE MKT Exchange in USA. It is located in 2173 Salk Avenue, Carlsbad, CA, United States, 92008 and employs 68 people. Lineage Cell is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 126.06 M. Lineage Cell Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 220.42 M outstanding shares of which 15.94 M shares are now shorted by private and institutional investors with about 35.21 trading days to cover.
Lineage Cell Therapeutics currently holds about 66.36 M in cash with (28.57 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.39.
Check Lineage Cell Probability Of Bankruptcy
Ownership AllocationLineage Cell Therapeutics maintains a total of 220.42 Million outstanding shares. Over half of Lineage Cell's outstanding shares are owned by institutional investors. These institutional investors are typically referred to as corporate investors that shop for positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Lineage Ownership Details
Lineage Cell Historical Income Statement
Lineage Stock Against Markets
Lineage Cell Corporate Management
| Charlotte Hubbert | Vice Development | Profile | |
| Jill Howe | CFO Officer | Profile | |
| DVM Dvm | VP Affairs | Profile | |
| Alexandra Hernandez | Senior Controller | Profile | |
| JD III | General Secretary | Profile | |
| Ioana Hone | Director Relations | Profile |
Additional Tools for Lineage Stock Analysis
When running Lineage Cell's price analysis, check to measure Lineage Cell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lineage Cell is operating at the current time. Most of Lineage Cell's value examination focuses on studying past and present price action to predict the probability of Lineage Cell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lineage Cell's price. Additionally, you may evaluate how the addition of Lineage Cell to your portfolios can decrease your overall portfolio volatility.